

Global and United States Oral hypoglycemic agents and insulin analogues In-Depth Research Report 2017-2022

<https://marketpublishers.com/r/GB9C27B105DEN.html>

Date: July 2017

Pages: 128

Price: US\$ 3,190.00 (Single User License)

ID: GB9C27B105DEN

Abstracts

The report is based on the market historical data from 2012 to 2016 and forecast the market trend from 2017 to 2022.

This report focuses on the U.S. market and presents volume and value of market share by players, by regions, by product type, by consumers and also changes in prices. As an in-depth report, it covers all details inside analysis and opinions in Oral hypoglycemic agents and insulin analogues industry.

Major Companies

ASTRAZENECA AB

AUROBINDO PHARMA LTD

BAYER HLTHCARE

BOEHRINGER INGELHEIM

CIPLA LTD

DR REDDYS LABS LTD

EPIC PHARMA LLC

HERITAGE PHARMS INC

IMPAX LABS

INVAGEN PHARMS

JANSSEN PHARMS

LABS LLC

LUPIN LTD

MACLEODS PHARMS LTD

MANNKIND

MERCK SHARP DOHME

MICRO LABS LTD INDIA

MYLAN

NOVO NORDISK INC

PADDOCK LLC

PAR PHARM

PFIZER

SANDOZ

SANOFI AVENTIS US

SANTARUS INC

SB PHARMCO

SUN PHARM INDS INC

TAKEDA PHARMS USA

TEVA

APOTEX

Key Regions

North America

United States

California

Texas

New York

Others

Canada

Latin America

Mexico

Brazil

Argentina

Others

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Netherland

Others

Asia & Pacific

China

Japan

India

Korea

Australia

Southeast Asia

Indonesia

Thailand

Philippines

Vietnam

Singapore

Malaysia

Others

Africa & Middle East

South Africa

Egypt

Turkey

Saudi Arabia

Iran

Others

Main types of products

Oral hypoglycemic agents and insulin analogues Market, by Insulin sensitizing agents

Metformin

Buformin

Phenformin

Pioglitazone

Rosiglitazone

Troglitazone

Aleglitazar

Muraglitazar

Tesaglitazar

Oral hypoglycemic agents and insulin analogues Market, by Secretagogue

Acetohexamide

Carbutamide

Chlorpropamide

Metahexamide

Tolazamide

Tolbutamide

Glibenclamide

Glibornuride

Glipizide

Gliquidone

Glisoxepide

Glycropyramide

Glimepiride

Gliclazide

Nateglinide

Repaglinide

Mitiglinide

Exenatide

Liraglutide

Lixisenatide

Linagliptin

Saxagliptin

Sitagliptin

Vildagliptin

Oral hypoglycemic agents and insulin analogues Market, by Insulin class

Insulin Lispro

Insulin aspart

Glulisine

insulin

insulin glargine

insulin detemir

neutral protamine Hagedorn insulin

Oral hypoglycemic agents and insulin analogues Market, by Others

Acarbose

Miglitol

Voglibose

Pramlintide

Benfluorex

Tolrestat

Oral hypoglycemic agents and insulin analogues Market, by Key Consumers

Department of endocrinology

Diabetes division

Pharmacy

Hospital

Contents

Global and United States Oral hypoglycemic agents and insulin analogues In-Depth Research Report 2017-2022

CHAPTER ONE GLOBAL ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES MARKET OVERVIEW

1.1 Global Oral hypoglycemic agents and insulin analogues Market Sales Volume Revenue and Price 2012-2017

1.2 Oral hypoglycemic agents and insulin analogues, by Insulin sensitizing agents 2012-2017

1.2.1 Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin sensitizing agents 2012-2017

1.2.2 Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin sensitizing agents 2012-2017

1.2.3 Global Oral hypoglycemic agents and insulin analogues Price by Insulin sensitizing agents 2012-2017

1.2.4 Metformin

1.2.5 Buformin

1.2.6 Phenformin

1.2.7 Pioglitazone

1.2.8 Rosiglitazone

1.2.8 Tolazamide

1.2.9 Troglitazone

1.2.10 Aloglitazar

1.2.11 Muraglitazar

1.2.12 Tesaglitazar

1.3 Oral hypoglycemic agents and insulin analogues, by Secretagogue 2012-2017

1.3.1 Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Secretagogue 2012-2017

1.3.2 Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Secretagogue 2012-2017

1.3.3 Global Oral hypoglycemic agents and insulin analogues Price by Secretagogue 2012-2017

1.3.4 Acetohexamide

1.3.5 Carbutamide

1.3.6 Chlorpropamide

1.3.7 Metahexamide

- 1.3.8 Tolazamide
- 1.3.9 Tolbutamide
- 1.3.10 Glibenclamide
- 1.3.11 Glibornuride
- 1.3.12 Glipizide
- 1.3.13 Gliquidone
- 1.3.14 Glisoxepide
- 1.3.15 Glycopyramide
- 1.3.16 Glimepiride
- 1.3.17 Gliclazide
- 1.3.18 Nateglinide
- 1.3.19 Repaglinide
- 1.3.20 Mitiglinide
- 1.3.21 Exenatide
- 1.3.22 Liraglutide
- 1.3.23 Lixisenatide
- 1.3.24 Linagliptin
- 1.3.25 Saxagliptin
- 1.3.26 Sitagliptin
- 1.2.37 Vildagliptin
- 1.4 Oral hypoglycemic agents and insulin analogues, by Insulin class 2012-2017
 - 1.4.1 Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin class 2012-2017
 - 1.4.2 Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin class 2012-2017
 - 1.4.3 Global Oral hypoglycemic agents and insulin analogues Price by Insulin class 2012-2017
 - 1.4.4 Insulin Lispro
 - 1.4.5 Insulin aspart
 - 1.4.6 Glulisine
 - 1.4.7 insulin
 - 1.4.8 insulin glargine
 - 1.4.9 neutral protamine Hagedorn insulin
- 1.5 Oral hypoglycemic agents and insulin analogues, by Others 2012-2017
 - 1.5.1 Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Others 2012-2017
 - 1.5.2 Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Others 2012-2017
 - 1.5.3 Global Oral hypoglycemic agents and insulin analogues Price by Others

2012-2017

- 1.5.4 Acarbose
- 1.5.5 Miglitol
- 1.5.6 Voglibose
- 1.5.7 Pramlintide
- 1.5.8 Benfluorex
- 1.5.9 Tolrestat

CHAPTER TWO UNITED STATES ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES MARKET OVERVIEW

2.1 United States Oral hypoglycemic agents and insulin analogues Market Sales Volume Revenue and Price 2012-2017

2.2 Oral hypoglycemic agents and insulin analogues, by Insulin sensitizing agents 2012-2017

2.2.1 United States Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin sensitizing agents 2012-2017

2.2.2 United States Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin sensitizing agents 2012-2017

2.2.3 United States Oral hypoglycemic agents and insulin analogues Price by Insulin sensitizing agents 2012-2017

2.2.4 Metformin

2.2.5 Buformin

2.2.6 Phenformin

2.2.7 Pioglitazone

2.2.8 Rosiglitazone

1.2.8 Tolazamide

1.2.9 Troglitazone

1.2.10 Aloglitazar

1.2.11 Muraglitazar

1.2.12 Tesaglitazar

2.3 Oral hypoglycemic agents and insulin analogues, by Secretagogue 2012-2017

2.3.1 United States Oral hypoglycemic agents and insulin analogues Sales Market Share by Secretagogue 2012-2017

2.3.2 United States Oral hypoglycemic agents and insulin analogues Revenue Market Share by Secretagogue 2012-2017

2.3.3 United States Oral hypoglycemic agents and insulin analogues Price by Secretagogue 2012-2017

2.3.4 Acetohexamide

- 2.3.5 Carbutamide
- 2.3.6 Chlorpropamide
- 2.3.7 Metahexamide
- 2.3.8 Tolazamide
- 1.3.9 Tolbutamide
- 1.3.10 Glibenclamide
- 1.3.11 Glibornuride
- 1.3.12 Glipizide
- 1.3.13 Gliquidone
- 1.3.14 Glisoxepide
- 1.3.15 Glyclopamide
- 1.3.16 Glimepiride
- 1.3.17 Gliclazide
- 1.3.18 Nateglinide
- 1.3.19 Repaglinide
- 1.3.20 Mitiglinide
- 1.3.21 Exenatide
- 1.3.22 Liraglutide
- 1.3.23 Lixisenatide
- 1.3.24 Linagliptin
- 1.3.25 Saxagliptin
- 1.3.26 Sitagliptin
- 1.2.37 Vildagliptin

2.4 Oral hypoglycemic agents and insulin analogues, by Insulin class 2012-2017

2.4.1 United States Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin class 2012-2017

2.4.2 United States Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin class 2012-2017

2.4.3 United States Oral hypoglycemic agents and insulin analogues Price by Insulin class 2012-2017

2.4.4 Insulin Lispro

2.4.5 Insulin aspart

2.4.6 Glulisine

2.4.7 insulin

2.4.8 insulin glargine

1.4.9 neutral protamine Hagedorn insulin

2.5 Oral hypoglycemic agents and insulin analogues, by Others 2012-2017

2.5.1 United States Oral hypoglycemic agents and insulin analogues Sales Market Share by Others 2012-2017

2.5.2 United States Oral hypoglycemic agents and insulin analogues Revenue Market Share by Others 2012-2017

2.5.3 United States Oral hypoglycemic agents and insulin analogues Price by Others 2012-2017

2.5.4 Acarbose

2.5.5 Miglitol

2.5.6 Voglibose

2.5.7 Pramlintide

2.5.8 Benfluorex

1.5.9 Tolrestat

CHAPTER THREE ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES BY REGIONS 2012-2017

3.1 Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Regions 2012-2017

3.2 Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Regions 2012-2017

3.3 Global Oral hypoglycemic agents and insulin analogues Price by Regions 2012-2017

3.4 North America

3.4.1 United States

3.4.1.1 California

3.4.1.2 Texas

3.4.1.3 New York

3.4.1.4 Others in United States

3.4.2 Canada

3.5 Latin America

3.5.1 Mexico

3.5.2 Brazil

3.5.3 Argentina

3.5.4 Others in Latin America

3.6 Europe

3.6.1 Germany

3.6.2 United Kingdom

3.6.3 France

3.6.4 Italy

3.6.5 Spain

3.6.6 Russia

- 3.6.7 Netherland
- 3.6.8 Others in Europe
- 3.7 Asia & Pacific
 - 3.7.1 China
 - 3.7.2 Japan
 - 3.7.3 India
 - 3.7.4 Korea
 - 3.7.5 Australia
 - 3.7.6 Southeast Asia
 - 3.7.6.1 Indonesia
 - 3.7.6.2 Thailand
 - 3.7.6.3 Philippines
 - 3.7.6.4 Vietnam
 - 3.7.6.5 Singapore
 - 3.7.6.6 Malaysia
 - 3.7.6.7 Others in Southeast Asia
- 3.8 Africa & Middle East
 - 3.8.1 South Africa
 - 3.8.2 Egypt
 - 3.8.3 Turkey
 - 3.8.4 Saudi Arabia
 - 3.8.5 Iran
 - 3.8.6 Others in Africa & Middle East

CHAPTER FOUR GLOBAL ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES BY COMPANIES 2012-2017

- 4.1 Global Oral hypoglycemic agents and insulin analogues Sales Volume Market Share by Companies 2012-2017
- 4.2 Global Oral hypoglycemic agents and insulin analogues Revenue Share by Companies 2012-2017
- 4.3 Global Top Companies Oral hypoglycemic agents and insulin analogues Key Product Model and Market Performance
- 4.4 Global Top Companies Oral hypoglycemic agents and insulin analogues Key Target Consumers and Market Performance

CHAPTER FIVE UNITED STATES ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES BY COMPANIES 2012-2017

5.1 United States Oral hypoglycemic agents and insulin analogues Sales Volume Market Share by Companies 2012-2017

5.2 United States Oral hypoglycemic agents and insulin analogues Revenue Share by Companies 2012-2017

5.3 United States Top Companies Oral hypoglycemic agents and insulin analogues Key Product Model and Market Performance

5.4 United States Top Companies Oral hypoglycemic agents and insulin analogues Key Target Consumers and Market Performance

CHAPTER SIX GLOBAL ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES BY CONSUMER 2012-2017

6.1 Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Consumer 2012-2017

6.2 Department of endocrinology

6.3 Diabetes division

6.4 Pharmacy

6.5 Hospital

6.6 Consuming Habit and Preference

CHAPTER SEVEN GLOBAL ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES BY CONSUMER 2012-2017

7.1 Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Consumer 2012-2017

7.2 Department of endocrinology

7.3 Diabetes division

7.4 Pharmacy

7.5 Hospital

7.6 Consuming Habit and Preference

CHAPTER EIGHT TOP COMPANIES PROFILE

8.1 ASTRAZENECA AB

8.1.1 ASTRAZENECA AB Company Details and Competitors

8.1.2 ASTRAZENECA AB Key Oral hypoglycemic agents and insulin analogues Models and Performance

8.1.3 ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

8.1.4 ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin

8.2 AUROBINDO PHARMA LTD

8.2.1 AUROBINDO PHARMA LTD Company Details and Competitors

8.2.2 AUROBINDO PHARMA LTD Key Oral hypoglycemic agents and insulin analogues Models and Performance

8.2.3 AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

8.2.4 AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin

8.3 BAYER HLTHCARE

8.3.1 BAYER HLTHCARE Company Details and Competitors

8.3.2 BAYER HLTHCARE Key Oral hypoglycemic agents and insulin analogues Models and Performance

8.3.3 BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

8.3.4 BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin

8.4 BOEHRINGER INGELHEIM

8.4.1 BOEHRINGER INGELHEIM Company Details and Competitors

8.4.2 BOEHRINGER INGELHEIM Key Oral hypoglycemic agents and insulin analogues Models and Performance

8.4.3 BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

8.4.4 BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin

8.5 CIPLA LTD

8.5.1 CIPLA LTD Company Details and Competitors

8.5.2 CIPLA LTD Key Oral hypoglycemic agents and insulin analogues Models and Performance

8.5.3 CIPLA LTD Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

8.5.4 CIPLA LTD Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin

8.6 DR REDDYS LABS LTD

8.6.1 DR REDDYS LABS LTD Company Details and Competitors

8.6.2 DR REDDYS LABS LTD Key Oral hypoglycemic agents and insulin analogues Models and Performance

8.6.3 DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues

Business SWOT Analysis and Forecast

8.6.4 DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin

8.7 EPIC PHARMA LLC

8.7.1 EPIC PHARMA LLC Company Details and Competitors

8.7.2 EPIC PHARMA LLC Key Oral hypoglycemic agents and insulin analogues Models and Performance

8.7.3 EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

8.7.4 EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin

8.8 HERITAGE PHARMS INC

8.8.1 HERITAGE PHARMS INC Company Details and Competitors

8.8.2 HERITAGE PHARMS INC Key Oral hypoglycemic agents and insulin analogues Models and Performance

8.8.3 HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

8.8.4 HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin

8.9 IMPAX LABS

8.9.1 IMPAX LABS Company Details and Competitors

8.9.2 IMPAX LABS Key Oral hypoglycemic agents and insulin analogues Models and Performance

8.9.3 IMPAX LABS Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

8.9.4 IMPAX LABS Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin

8.10 INVAGEN PHARMS

8.10.1 INVAGEN PHARMS Company Details and Competitors

8.10.2 INVAGEN PHARMS Key Oral hypoglycemic agents and insulin analogues Models and Performance

8.10.3 INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

8.10.4 INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Sales Volume Revenue Price Cost and Gross Margin

8.11 JANSSEN PHARMS

8.12 LABS LLC

8.13 LUPIN LTD

8.14 MACLEODS PHARMS LTD

- 8.15 MANNKIND
- 8.16 MERCK SHARP DOHME
- 8.17 MICRO LABS LTD INDIA
- 8.18 MYLAN
- 8.19 NOVO NORDISK INC
- 8.20 PADDOCK LLC
- 8.21 PAR PHARM
- 8.22 PFIZER
- 8.23 SANDOZ
- 8.24 SANOFI AVENTIS US
- 8.25 SANTARUS INC
- 8.26 SB PHARMCO
- 8.27 SUN PHARM INDS INC
- 8.28 TAKEDA PHARMS USA
- 8.29 TEVA
- 8.30 APOTEX

CHAPTER NINE INDUSTRY CHAIN AND SUPPLY CHAIN

- 9.1 Oral hypoglycemic agents and insulin analogues Industry Chain Structure
 - 9.1.1 R&D
 - 9.1.2 Raw Materials (Components)
 - 9.1.3 Manufacturing Plants
 - 9.1.4 Regional Trading (Import Export and Local Sales)
 - 9.1.5 Online Sales Channel
 - 9.1.6 Offline Channel
 - 9.1.7 End Users
- 9.2 Oral hypoglycemic agents and insulin analogues Manufacturing
 - 9.2.1 Key Components
 - 9.2.2 Assembly Manufacturing
- 9.3 Consumer Preference
- 9.4 Behavioral Habits
- 9.5 Marketing Environment

CHAPTER TEN GLOBAL ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

- 10.1 Global Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD) Forecast (2017-2022)

10.2 Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Regions (2017-2022)

10.3 Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Application (2017-2022)

10.4 Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Insulin sensitizing agents (2017-2022)

10.5 Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Secretagogue (2017-2022)

10.6 Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Insulin class (2017-2022)

10.7 Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Others (2017-2022)

CHAPTER ELEVEN UNITED STATES ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

11.1 United States Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD) Forecast (2017-2022)

11.2 United States Oral hypoglycemic agents and insulin analogues Sales () Forecast by Regions (2017-2022)

11.3 United States Oral hypoglycemic agents and insulin analogues Sales () Forecast by Application (2017-2022)

11.4 United States Oral hypoglycemic agents and insulin analogues Sales () Forecast by Insulin sensitizing agents (2017-2022)

11.5 United States Oral hypoglycemic agents and insulin analogues Sales () Forecast by Secretagogue (2017-2022)

11.6 United States Oral hypoglycemic agents and insulin analogues Sales () Forecast by Insulin class (2017-2022)

11.7 United States Oral hypoglycemic agents and insulin analogues Sales () Forecast by Others (2017-2022)

CHAPTER TWELVE DEVELOPMENT TREND AND RESEARCH CONCLUSION

12.1 Development Trend

12.2 Research Conclusion

CHAPTER THIRTEEN METHODOLOGY AND DATA SOURCE

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

List Of Tables

LIST OF TABLES AND FIGURES

Table Global Oral hypoglycemic agents and insulin analogues Sales Volume (), Revenue (Million USD) and Price () (2012-2017)

Figure Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Growth Rate (2012-2017)

Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume () and Growth Rate (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Sales () by Insulin sensitizing agents (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin sensitizing agents (2012-2017)

Figure Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin sensitizing agents in 2016

Table Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Insulin sensitizing agents (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin sensitizing agents (2012-2017)

Figure Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin sensitizing agents in 2016

Table Global Oral hypoglycemic agents and insulin analogues Price () by Insulin sensitizing agents (2012-2017)

Table Top Companies of Metformin Oral hypoglycemic agents and insulin analogues Products List

Figure Global Metformin Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table Top Companies of Buformin Oral hypoglycemic agents and insulin analogues Products List

Figure Global Buformin Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table Top Companies of Phenformin Oral hypoglycemic agents and insulin analogues Products List

Figure Global Phenformin Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table Top Companies of Pioglitazone Oral hypoglycemic agents and insulin analogues Products List

Figure Global Pioglitazone Oral hypoglycemic agents and insulin analogues Sales ()

and Growth Rate (2012-2017)

Table Top Companies of Rosiglitazone Oral hypoglycemic agents and insulin analogues Products List

Figure Global Rosiglitazone Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Sales () by Secretagogue (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Secretagogue (2012-2017)

Figure Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Secretagogue in 2016

Table Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Secretagogue (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Secretagogue (2012-2017)

Figure Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Secretagogue in 2016

Table Global Oral hypoglycemic agents and insulin analogues Price () by Secretagogue (2012-2017)

Table Top Companies of Acetohexamide Oral hypoglycemic agents and insulin analogues Products List

Figure Global Acetohexamide Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table Top Companies of Carbutamide Oral hypoglycemic agents and insulin analogues Products List

Figure Global Carbutamide Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table Top Companies of Chlorpropamide Oral hypoglycemic agents and insulin analogues Products List

Figure Global Chlorpropamide Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table Top Companies of Metahexamide Oral hypoglycemic agents and insulin analogues Products List

Figure Global Metahexamide Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table Top Companies of Tolazamide Oral hypoglycemic agents and insulin analogues Products List

Figure Global Tolazamide Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Sales (€) by Insulin class (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin class (2012-2017)

Figure Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin class in 2016

Table Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Insulin class (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin class (2012-2017)

Figure Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin class in 2016

Table Global Oral hypoglycemic agents and insulin analogues Price (€) by Insulin class (2012-2017)

Table Top Companies of Insulin Lispro Oral hypoglycemic agents and insulin analogues Products List

Figure Global Insulin Lispro Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Top Companies of Insulin aspart Oral hypoglycemic agents and insulin analogues Products List

Figure Global Insulin aspart Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Top Companies of Glulisine Oral hypoglycemic agents and insulin analogues Products List

Figure Global Glulisine Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Top Companies of insulin Oral hypoglycemic agents and insulin analogues Products List

Figure Global insulin Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Top Companies of insulin glargine Oral hypoglycemic agents and insulin analogues Products List

Figure Global insulin glargine Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Sales (€) by Others (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Others (2012-2017)

Figure Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Others (2012-2017)

Others in 2016

Table Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Others (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Others (2012-2017)

Figure Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Others in 2016

Table Global Oral hypoglycemic agents and insulin analogues Price (€) by Others (2012-2017)

Table Top Companies of Acarbose Oral hypoglycemic agents and insulin analogues Products List

Figure Global Acarbose Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Top Companies of Miglitol Oral hypoglycemic agents and insulin analogues Products List

Figure Global Miglitol Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Top Companies of Voglibose Oral hypoglycemic agents and insulin analogues Products List

Figure Global Voglibose Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Top Companies of Pramlintide Oral hypoglycemic agents and insulin analogues Products List

Figure Global Pramlintide Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Top Companies of Benfluorex Oral hypoglycemic agents and insulin analogues Products List

Figure Global Benfluorex Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Figure United States Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Growth Rate (2012-2017)

Figure United States Oral hypoglycemic agents and insulin analogues Sales Volume (€) and Growth Rate (2012-2017)

Table United States Oral hypoglycemic agents and insulin analogues Sales (€) by Insulin sensitizing agents (2012-2017)

Table United States Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin sensitizing agents (2012-2017)

Figure United States Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin sensitizing agents in 2016

Table United States Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Insulin sensitizing agents (2012-2017)

Table United States Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin sensitizing agents (2012-2017)

Figure United States Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin sensitizing agents in 2016

Table United States Oral hypoglycemic agents and insulin analogues Price (\$) by Insulin sensitizing agents (2012-2017)

Table Top Companies of Metformin Oral hypoglycemic agents and insulin analogues Products List

Figure United States Metformin Oral hypoglycemic agents and insulin analogues Sales (\$) and Growth Rate (2012-2017)

Table Top Companies of Buformin Oral hypoglycemic agents and insulin analogues Products List

Figure United States Buformin Oral hypoglycemic agents and insulin analogues Sales (\$) and Growth Rate (2012-2017)

Table Top Companies of Phenformin Oral hypoglycemic agents and insulin analogues Products List

Figure United States Phenformin Oral hypoglycemic agents and insulin analogues Sales (\$) and Growth Rate (2012-2017)

Table Top Companies of Pioglitazone Oral hypoglycemic agents and insulin analogues Products List

Figure United States Pioglitazone Oral hypoglycemic agents and insulin analogues Sales (\$) and Growth Rate (2012-2017)

Table Top Companies of Rosiglitazone Oral hypoglycemic agents and insulin analogues Products List

Figure United States Rosiglitazone Oral hypoglycemic agents and insulin analogues Sales (\$) and Growth Rate (2012-2017)

Table United States Oral hypoglycemic agents and insulin analogues Sales (\$) by Secretagogue (2012-2017)

Table United States Oral hypoglycemic agents and insulin analogues Sales Market Share by Secretagogue (2012-2017)

Figure United States Oral hypoglycemic agents and insulin analogues Sales Market Share by Secretagogue in 2016

Table United States Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Secretagogue (2012-2017)

Table United States Oral hypoglycemic agents and insulin analogues Revenue Market Share by Secretagogue (2012-2017)

Figure United States Oral hypoglycemic agents and insulin analogues Revenue Market

Share by Secretagogue in 2016

Table United States Oral hypoglycemic agents and insulin analogues Price (€) by Secretagogue (2012-2017)

Table Top Companies of Acetohexamide Oral hypoglycemic agents and insulin analogues Products List

Figure United States Acetohexamide Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Top Companies of Carbutamide Oral hypoglycemic agents and insulin analogues Products List

Figure United States Carbutamide Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Top Companies of Chlorpropamide Oral hypoglycemic agents and insulin analogues Products List

Figure United States Chlorpropamide Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Top Companies of Metahexamide Oral hypoglycemic agents and insulin analogues Products List

Figure United States Metahexamide Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Top Companies of Tolazamide Oral hypoglycemic agents and insulin analogues Products List

Figure United States Tolazamide Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table United States Oral hypoglycemic agents and insulin analogues Sales (€) by Insulin class (2012-2017)

Table United States Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin class (2012-2017)

Figure United States Oral hypoglycemic agents and insulin analogues Sales Market Share by Insulin class in 2016

Table United States Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Insulin class (2012-2017)

Table United States Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin class (2012-2017)

Figure United States Oral hypoglycemic agents and insulin analogues Revenue Market Share by Insulin class in 2016

Table United States Oral hypoglycemic agents and insulin analogues Price (€) by Insulin class (2012-2017)

Table Top Companies of Insulin Lispro Oral hypoglycemic agents and insulin analogues Products List

Figure United States Insulin Lispro Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Top Companies of Insulin aspart Oral hypoglycemic agents and insulin analogues Products List

Figure United States Insulin aspart Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Top Companies of Glulisine Oral hypoglycemic agents and insulin analogues Products List

Figure United States Glulisine Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Top Companies of insulin Oral hypoglycemic agents and insulin analogues Products List

Figure United States insulin Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Top Companies of insulin glargine Oral hypoglycemic agents and insulin analogues Products List

Figure United States insulin glargine Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table United States Oral hypoglycemic agents and insulin analogues Sales (€) by Others (2012-2017)

Table United States Oral hypoglycemic agents and insulin analogues Sales Market Share by Others (2012-2017)

Figure United States Oral hypoglycemic agents and insulin analogues Sales Market Share by Others in 2016

Table United States Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Others (2012-2017)

Table United States Oral hypoglycemic agents and insulin analogues Revenue Market Share by Others (2012-2017)

Figure United States Oral hypoglycemic agents and insulin analogues Revenue Market Share by Others in 2016

Table United States Oral hypoglycemic agents and insulin analogues Price (€) by Others (2012-2017)

Table Top Companies of Acarbose Oral hypoglycemic agents and insulin analogues Products List

Figure United States Acarbose Oral hypoglycemic agents and insulin analogues Sales (€) and Growth Rate (2012-2017)

Table Top Companies of Miglitol Oral hypoglycemic agents and insulin analogues Products List

Figure United States Miglitol Oral hypoglycemic agents and insulin analogues Sales (€)

and Growth Rate (2012-2017)

Table Top Companies of Voglibose Oral hypoglycemic agents and insulin analogues Products List

Figure United States Voglibose Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table Top Companies of Pramlintide Oral hypoglycemic agents and insulin analogues Products List

Figure United States Pramlintide Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table Top Companies of Benfluorex Oral hypoglycemic agents and insulin analogues Products List

Figure United States Benfluorex Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Sales () by Regions (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Sales Share by Regions (2012-2017)

Figure Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Regions in 2016

Figure Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Regions in 2017

Table Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share by Regions (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Regions (2012-2017)

Figure Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Regions in 2016

Figure Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Regions in 2017

Table Global Oral hypoglycemic agents and insulin analogues Price () by Regions (2012-2017)

Table North America Oral hypoglycemic agents and insulin analogues Sales () by Regions (2012-2017)

Table North America Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Regions (2012-2017)

Figure North America Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table United States Oral hypoglycemic agents and insulin analogues Sales () by Regions (2012-2017)

Table United States Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Regions (2012-2017)

Figure United States Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table Latin America Oral hypoglycemic agents and insulin analogues Sales () by Regions (2012-2017)

Table Latin America Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Regions (2012-2017)

Figure Latin America Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table Europe Oral hypoglycemic agents and insulin analogues Sales () by Regions (2012-2017)

Table Europe Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Regions (2012-2017)

Figure Europe Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table Asia & Pacific Oral hypoglycemic agents and insulin analogues Sales () by Regions (2012-2017)

Table Asia & Pacific Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Regions (2012-2017)

Figure Asia & Pacific Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table Africa & Middle East Oral hypoglycemic agents and insulin analogues Sales () by Regions (2012-2017)

Table Africa & Middle East Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Regions (2012-2017)

Figure Africa & Middle East Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Sales Volume () by Major Companies (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Sales Volume Market Share by Major Companies (2012-2017)

Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume Market Share by Major Companies 2016

Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume Market Share by Major Companies 2017

Table Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Major Companies (2012-2017)

Table Global Oral hypoglycemic agents and insulin analogues Revenue Market Share

by Major Companies (2012-2017)

Figure Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Major Companies 2016

Figure Global Oral hypoglycemic agents and insulin analogues Revenue Market Share by Major Companies 2017

Table Global Top Companies Key Product Model and Market Performance

Table Global Top Companies Key Target Consumers and Market Performance

Table United States Oral hypoglycemic agents and insulin analogues Sales Volume () by Top Companies (2012-2017)

Table United States Oral hypoglycemic agents and insulin analogues Sales Volume Market Share by Top Companies (2012-2017)

Figure United States Oral hypoglycemic agents and insulin analogues Sales Volume Market Share by Top Companies 2016

Figure United States Oral hypoglycemic agents and insulin analogues Sales Volume Market Share by Top Companies 2017

Table United States Oral hypoglycemic agents and insulin analogues Revenue (Million USD) by Top Companies (2012-2017)

Table United States Oral hypoglycemic agents and insulin analogues Revenue Market Share by Top Companies (2012-2017)

Figure United States Oral hypoglycemic agents and insulin analogues Revenue Market Share by Top Companies 2016

Figure United States Oral hypoglycemic agents and insulin analogues Revenue Market Share by Top Companies 2017

Table United States Top Companies Key Product Model and Market Performance

Table United States Top Companies Key Target Consumers and Market Performance

Table Global Oral hypoglycemic agents and insulin analogues Sales () by Consumer (2012-2017)

Figure Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Consumer (2012-2017)

Figure Global Oral hypoglycemic agents and insulin analogues Sales Market Share by Consumer in 2016

Figure Global Department of endocrinology Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Figure Global Diabetes division Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Figure Global Pharmacy Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Figure Global Hospital Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table United States Oral hypoglycemic agents and insulin analogues Sales () by Consumer (2012-2017)

Figure United States Oral hypoglycemic agents and insulin analogues Sales Market Share by Consumer (2012-2017)

Figure United States Oral hypoglycemic agents and insulin analogues Sales Market Share by Consumer in 2016

Figure United States Department of endocrinology Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Figure United States Diabetes division Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Figure United States Pharmacy Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Figure United States Hospital Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (2012-2017)

Table ASTRAZENECA AB Company Details and Competitors

Table ASTRAZENECA AB Key Oral hypoglycemic agents and insulin analogues Models and Performance

Table ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

Table ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)

Figure ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)

Table AUROBINDO PHARMA LTD Company Details and Competitors

Table AUROBINDO PHARMA LTD Key Oral hypoglycemic agents and insulin analogues Models and Performance

Table AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

Table AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues

Sales Market Share (%) in Global (2012-2017)

Figure AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)

Table BAYER HLTHCARE Company Details and Competitors

Table BAYER HLTHCARE Key Oral hypoglycemic agents and insulin analogues Models and Performance

Table BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

Table BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)

Figure BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)

Table BOEHRINGER INGELHEIM Company Details and Competitors

Table BOEHRINGER INGELHEIM Key Oral hypoglycemic agents and insulin analogues Models and Performance

Table BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

Table BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)

Figure BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)

Table CIPLA LTD Company Details and Competitors

Table CIPLA LTD Key Oral hypoglycemic agents and insulin analogues Models and Performance

Table CIPLA LTD Oral hypoglycemic agents and insulin analogues Business SWOT

Analysis and Forecast

Table CIPLA LTD Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure CIPLA LTD Oral hypoglycemic agents and insulin analogues Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure CIPLA LTD Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)

Figure CIPLA LTD Oral hypoglycemic agents and insulin analogues Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure CIPLA LTD Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)

Table DR REDDYS LABS LTD Company Details and Competitors

Table DR REDDYS LABS LTD Key Oral hypoglycemic agents and insulin analogues Models and Performance

Table DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

Table DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)

Figure DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)

Table EPIC PHARMA LLC Company Details and Competitors

Table EPIC PHARMA LLC Key Oral hypoglycemic agents and insulin analogues Models and Performance

Table EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

Table EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)

Figure EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)

Table HERITAGE PHARMS INC Company Details and Competitors

Table HERITAGE PHARMS INC Key Oral hypoglycemic agents and insulin analogues Models and Performance

Table HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

Table HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)

Figure HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)

Table IMPAX LABS Company Details and Competitors

Table IMPAX LABS Key Oral hypoglycemic agents and insulin analogues Models and Performance

Table IMPAX LABS Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

Table IMPAX LABS Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure IMPAX LABS Oral hypoglycemic agents and insulin analogues Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure IMPAX LABS Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)

Figure IMPAX LABS Oral hypoglycemic agents and insulin analogues Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure IMPAX LABS Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)

Table INVAGEN PHARMS Company Details and Competitors

Table INVAGEN PHARMS Key Oral hypoglycemic agents and insulin analogues Models and Performance

Table INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Business SWOT Analysis and Forecast

Table INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Output (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Figure INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Sales (Million Unit) and Growth Rate (%) (2012-2017)

Figure INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Global (2012-2017)

Figure INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Sales Revenue (Million USD) and Growth Rate (%) (2012-2017)

Figure INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Global (2012-2017)

Table JANSSEN PHARMS Company Details and Competitors

Table LABS LLC Company Details and Competitors

Table LUPIN LTD Company Details and Competitors

Table MACLEODS PHARMS LTD Company Details and Competitors

Table MANNKIND Company Details and Competitors

Table MERCK SHARP DOHME Company Details and Competitors

Table MICRO LABS LTD INDIA Company Details and Competitors

Table MYLAN Company Details and Competitors

Table NOVO NORDISK INC Company Details and Competitors

Table PADDOCK LLC Company Details and Competitors

Table PAR PHARM Company Details and Competitors

Table PFIZER Company Details and Competitors

Table SANDOZ Company Details and Competitors

Table SANOFI AVENTIS US Company Details and Competitors

Table SANTARUS INC Company Details and Competitors

Table SB PHARMCO Company Details and Competitors

Table SUN PHARM INDS INC Com

I would like to order

Product name: Global and United States Oral hypoglycemic agents and insulin analogues In-Depth Research Report 2017-2022

Product link: <https://marketpublishers.com/r/GB9C27B105DEN.html>

Price: US\$ 3,190.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB9C27B105DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

